News
PMASS 2024 Speaker, Tony Dzung: Automating Marketing with AI, the Key to Breakthroughs in the Pharmaceutical Industry
The PMASS 2024 Pharma Marketing and Sales Forum, themed “Generative AI in Pharma,” will provide fresh and promising perspectives on the role of generative intelligence in the pharmaceutical industry. In the context of rapidly advancing technology, the application of Generative AI is opening up tremendous opportunities for the pharmaceutical industry, from optimizing research and product development processes to creating media content and enhancing customer experiences.
To provide a comprehensive perspective on Generative AI, the PMASS 2024 organizing committee has invited Mr. Tony Dzung – one of the leading speakers in Vietnam on marketing, human resource management, and especially AI technology. Originally an IT guy who graduated from Hanoi University of Science and Technology, Mr. Tony Dzung is currently the Chairman of the Board of HBR Holdings, overseeing a large educational ecosystem with over 1,400 employees and owning several well-known brands such as Langmaster and HBR Business School.
With over 15 years of experience in training and business development, his presentation “Automating Pharmaceutical Marketing with AI” at PMASS 2024 promises to provide pharmaceutical companies with valuable practical knowledge and innovative solutions, helping them to optimally leverage the potential of Generative AI in sustainable development strategies.
Let’s join the MPG Medical Marketing Academy in discussing with Mr. Nguyễn Tiến Dũng about the role of Generative AI in the pharmaceutical industry ahead of PMASS 2024.
What is your assessment of the PMASS Pharmaceutical Marketing and Sales Forum, the largest event in the pharmaceutical industry?
I highly appreciate PMASS, an in-depth forum for the pharmaceutical industry, which has made a mark with 5 seasons of resounding success since its launch in 2019. This event not only gathers esteemed speakers, who are seasoned experts in the fields of Pharmacy and brand communication, but also attracts hundreds of CEOs and senior managers from major companies as guests.
With diverse themes and multifaceted discussions, PMASS is not only a place to update the latest knowledge and trends in marketing and pharmaceutical business but also a source of inspiration for pharmaceutical companies to boldly innovate, apply technology, and keep pace with other industries. This not only helps them optimize their business operations but also enhances their competitiveness in the rapidly changing market landscape.
Despite a very busy schedule, what motivated you to agree to participate in PMASS 2024?
In the process of consulting and training businesses, I have noticed that the application of technology, especially artificial intelligence (AI), has not only become an inevitable trend but also a golden key to enhancing operational efficiency. That is the reason why I decided to share at PMASS 2024, with the hope:
- Help businesses in the pharmaceutical industry gain additional perspectives and practical knowledge in applying AI to marketing activities.
- Help everyone optimize their workflows while also opening up new opportunities to increase customer reach, enhance experiences, and improve service quality.
Can you reveal the topic you will be sharing at PMASS 2024?
At PMASS 2024, I chose the topic “Automating Pharmaceutical Marketing with AI” because I believe that the application of AI Automation will be a crucial turning point for pharmaceutical companies to optimize costs and increase efficiency to break through in this digital era. AI not only helps reduce dependence on human resources, allowing businesses to scale flexibly, but also enhances service quality through the use of accurate data and analysis.AI not only helps reduce dependence on human resources, allowing businesses to scale flexibly, but also enhances service quality through the use of precise data and analytics.
Can you share the biggest challenges the pharmaceutical industry faces when applying AI to marketing activities?
First, many pharmaceutical business leaders lack fundamental knowledge of marketing, leading to the application of AI in a “patchwork” manner without a clear strategy. This directly affects the effectiveness of technology application, causing many businesses to struggle during the implementation process.
Secondly, the corporate culture is not yet ready for innovation, lacking a learning motivation and not implementing decisively, causing the workforce to be unable to adapt to new working methods based on AI and data.
Thirdly, the lack of AI experts or partners with practical experience to provide consulting support will significantly impact the success of the business during the AI application testing process.
Additionally, the lack of a positive learning environment is also a significant barrier, easily leading to resistance among personnel in the system due to concerns about being replaced by technology.
Finally, the shortage of personnel with knowledge and skills in AI is also a significant obstacle for the pharmaceutical industry and is not easy to resolve in the short term.
So, do you have any advice for pharmaceutical companies that are just starting to apply AI in their marketing activities?
First of all, I advise pharmaceutical business leaders to build a solid foundation of marketing knowledge so they can make accurate decisions and apply AI effectively and selectively, rather than succumbing to FOMO and following the crowd.
Secondly, businesses need to encourage a spirit of continuous learning and build an open culture with data-driven and AI-based working methods to create a sustainable foundation for development.
Thirdly, businesses should seek and collaborate with experts who have practical experience in AI application, especially those who have succeeded in similar projects, as this will help the business establish a more specific and effective roadmap.
Fourth, businesses should create a dynamic work environment where people can share experiences and learn from each other, helping to promote the synchronized and effective application of AI.
Finally, leaders should focus on recruiting and training employees who can adapt to AI, while also encouraging staff to overcome their concerns about AI to create sustainable value for the business together.
In your opinion, what trends will shape the future of the pharmaceutical industry in the coming time?
I believe that artificial intelligence along with big data will change the way businesses care for and serve their customers. When AI helps businesses personalize services, customers will receive a better experience, thereby increasing satisfaction and loyalty. This not only helps increase revenue but also enables pharmaceutical companies to build a long-term competitive advantage.
Businesses need to quickly adapt to technological trends, invest in infrastructure and data culture to maximize the potential of AI. It can be said that AI is a crucial foundation, helping pharmaceutical companies not only keep up but also lead the market in the digital era.
Let’s talk to Mr. Tony Dzung, who has opened up valuable insights about the potential of AI in Marketing, especially “AI automation,” a concept still quite new to the Pharmaceutical industry. And we look forward to seeing you at PMASS 2024 in Ho Chi Minh City on the afternoon of November 28, 2024.
